Search for a trial

A Single dose, two-way crossover study of the bioequivalence of two formulations of Ribavirin

To assess the bioequivalence of two marketed formulations of ribavirin (ribavirin solution and capsules).

A phase I, open-label, randomized, three-way cross-over study comparing bioavailability of two formulations and assessing the food effect on tablet formulation after PXL770 single oral dose in healthy subjects

The purpose of this study is compare a tablet formulation of PXL770 to the capsule formulation of PXL770. It will be investigated how quickly and to what extent PXL770 in each formulation is absorbed and eliminated from the body. To limit the…

A Double-Blind, Placebo-Controlled, Cross-over Phase II Study to Evaluate the Effect of a 6-week Elafibranor (120mg) treatment administered once daily on hepatic lipid composition in subjects with Nonalcoholic Fatty Liver (NAFL).

Primary Objective * To evaluate the effect of a 6-week treatment with elafibranor versus placebo on hepatic lipid composition in subjects with a fatty liver.Secondary objectives * To evaluate the between treatment difference (elafibranor 120 mg/d vs…

A phase I, open-label, randomized, 4-way crossover study in subjects with chronic Hepatitis B virus infection to assess pharmacokinetics (fasted/fed), safety, tolerability and pharmacodynamics of single oral doses of Farnesoid X receptor agonist EYP001a.

The purpose of the study is to investigate how quickly and to what extent EYP001a is absorbed into, distributed in and eliminated from the body (this is called pharmacokinetics) when EYP001a is administered with and without food. It will also be…